A little history
myNEO was founded in 2018 by leading biotech entrepreneurs combining expertise from different academic institutions. Cedric Bogaert, Jan Van Den Berghe, and Wim van Criekinge have since then expanded the team with established domain in antigen discovery experts as well as ambitious talent to further grow the company's innovation and developments.
To date, myNEO has achieved several pivotal milestones in realizing its vision. These include:
- Development of state-of-the-art antigen prediction algorithms
- Discovery of novel, dark antigen targets called camyotopes
- (Co-)development of novel immunotherapeutics products via strategic collaborations or in-house, leading to 3 separate programs executing successful IND/CTA filings in 2025
- The publication of high-impact scientific papers
- ISO and regulatory approval for clinical use of technology
- Securing valuable intellectual property with multiple patents
- Receiving several prestigious awards (Most Disruptive Innovator, Forbes 30under30, Rising Star Fast50)
The people behind myNEO
Team
Cedric Bogaert
Chief Executive Officer & Co-founder
Bert Coessens PhD
Chief Operating Officer
Bruno Fant PhD
Chief Scientific Officer
Lien Lybaert PhD
Chief Development Officer
Lore Van Oudenhove
Chief Technology Officer
Lena Pfitzer
Senior data scientist
Gitta Boons PhD
Senior data scientist
Manon Montyne
Principal data scientist
Jens De Ceukeleire
Principal data scientist
Emiel Evenepoel
Junior bioinformatician
Marie Van Hecke PhD
Junior bioinformatician
Sofie Pontzeele
Executive assistant
Bert Coessens PhD
Chief Operating Officer
Bert Coessens has a background in molecular biology and a PhD in advanced statistical analysis of 'omics' data. He was one of the founders of Cartagenia, a joint spin-off from the KU Leuven Dept. Electrotechniek (ESAT) and UZ Leuven Center for Human Genetics incorporated in 2008. At Cartagenia he led the quickly growing bioinformatics and software development teams, while in parallel successfully introducing both an ISO13485 certified Quality Management System, as well as an ISO27001 certified Information Security Management System into the organization. In May 2015 Cartagenia was acquired by Agilent, where Bert served as a Software R&D Manager, and later became Software R&D Director in the Agilent Genomics business unit.
At the end of 2018, Bert started his own consulting firm Perifora. Perifora specialises in 'as-a-service' business models that leverage the power and scalability of today's world-wide cloud infrastructure to bring products to the market in a secure and compliant way.